ALK and non-small cell lung carcinoma: Phase Ib KEYNOTE-200 investigated the intravenously delivered oncolytic virus Coxsackievirus A21 (CVA21, CAVATAK) in combination with pembrolizumab in advanced NSCLC and bladder cancer, demonstrating encouraging overall responses of 23% and 33% in 31 ICI-naïve and 21 EGFR/ALK mutation-negative NSCLC patients, respectively (84).